Do analysts prefer GNPX or ADXS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GNPX or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% Ayala Pharmaceuticals N/A N/A N/A

Do analysts recommend ALGS or GNPX?

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 575.44%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALGS or GNPX more profitable?

Genprex has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -1,919.68% -139.47% -90.88% Genprex N/A -247.32% -176.73%

Does the media favor ALGS or GNPX?

In the previous week, Aligos Therapeutics had 1 more articles in the media than Genprex. MarketBeat recorded 4 mentions for Aligos Therapeutics and 3 mentions for Genprex. Aligos Therapeutics' average media sentiment score of 0.86 beat Genprex's score of 0.48 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genprex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GNPX or DARE?

Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 348.43%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is GNPX or DARE more profitable?

Dare Bioscience's return on equity of 0.00% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -247.32% -176.73% Dare Bioscience N/A N/A -46.22%

Does the media prefer GNPX or DARE?

In the previous week, Dare Bioscience had 2 more articles in the media than Genprex. MarketBeat recorded 5 mentions for Dare Bioscience and 3 mentions for Genprex. Dare Bioscience's average media sentiment score of 0.61 beat Genprex's score of 0.48 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Dare Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VIRI or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, VIRI or GNPX?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Genprex N/A N/A -$16.23M -$14.14 N/A

Is VIRI or GNPX more profitable?

Virios Therapeutics' return on equity of -130.33% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Genprex N/A -247.32% -176.73%

Does the media favor VIRI or GNPX?

In the previous week, Genprex had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Genprex and 1 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.75 beat Genprex's score of 0.48 indicating that Virios Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virios Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genprex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TAOX or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TAOX or GNPX more profitable?

Synaptogenix's return on equity of -163.40% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Genprex N/A -247.32% -176.73%

Genprex (GNPX) Competitors

$0.78 -0.02 (-1.91%)

Closing price 04:00 PM Eastern

Extended Trading

$0.79 +0.01 (+1.60%)

As of 06:51 PM Eastern

Compare

GNPX vs. ADXS, ALGS, DARE, VIRI, and TAOX

Should you buy Genprex stock or one of its competitors? MarketBeat compares Genprex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genprex include Ayala Pharmaceuticals (ADXS), Aligos Therapeutics (ALGS), Dare Bioscience (DARE), Virios Therapeutics (VIRI), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry.

How does Genprex compare to Ayala Pharmaceuticals?

Genprex (NASDAQ:GNPX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Genprex has a beta of -0.94, meaning that its stock price is 194% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Ayala Pharmaceuticals' return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
Ayala Pharmaceuticals	N/A	N/A	N/A

Genprex has higher earnings, but lower revenue than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

14.1% of Genprex shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 0.3% of Genprex shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Genprex had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Genprex and 0 mentions for Ayala Pharmaceuticals. Genprex's average media sentiment score of 0.48 beat Ayala Pharmaceuticals' score of 0.00 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Neutral
Ayala Pharmaceuticals	Neutral

Summary

Genprex and Ayala Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Genprex compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Genprex has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	16.11	-$24.19M	-$8.69	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 575.44%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genprex has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Genprex	N/A	-247.32%	-176.73%

Aligos Therapeutics has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market. Comparatively, Genprex has a beta of -0.94, meaning that its stock price is 194% less volatile than the broader market.

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aligos Therapeutics had 1 more articles in the media than Genprex. MarketBeat recorded 4 mentions for Aligos Therapeutics and 3 mentions for Genprex. Aligos Therapeutics' average media sentiment score of 0.86 beat Genprex's score of 0.48 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genprex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aligos Therapeutics beats Genprex on 13 of the 16 factors compared between the two stocks.

How does Genprex compare to Dare Bioscience?

Genprex (NASDAQ:GNPX) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Dare Bioscience's return on equity of 0.00% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-247.32%	-176.73%
Dare Bioscience	N/A	N/A	-46.22%

In the previous week, Dare Bioscience had 2 more articles in the media than Genprex. MarketBeat recorded 5 mentions for Dare Bioscience and 3 mentions for Genprex. Dare Bioscience's average media sentiment score of 0.61 beat Genprex's score of 0.48 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genprex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dare Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dare Bioscience has higher revenue and earnings than Genprex. Dare Bioscience is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A
Dare Bioscience	$1.03M	32.43	-$13.40M	-$0.95	N/A

Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 348.43%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

14.1% of Genprex shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 0.3% of Genprex shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genprex has a beta of -0.94, indicating that its share price is 194% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Summary

Dare Bioscience beats Genprex on 12 of the 14 factors compared between the two stocks.

How does Genprex compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Genprex has a beta of -0.94, meaning that its share price is 194% less volatile than the broader market.

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

In the previous week, Genprex had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Genprex and 1 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.75 beat Genprex's score of 0.48 indicating that Virios Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virios Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genprex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virios Therapeutics' return on equity of -130.33% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Genprex	N/A	-247.32%	-176.73%

Summary

Virios Therapeutics beats Genprex on 7 of the 11 factors compared between the two stocks.

How does Genprex compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Genprex (NASDAQ:GNPX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 0.3% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Synaptogenix has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Genprex has a beta of -0.94, suggesting that its share price is 194% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Genprex had 2 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Genprex and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.89 beat Genprex's score of 0.48 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Overall Sentiment
Synaptogenix	Very Positive
Genprex	Neutral

Synaptogenix's return on equity of -163.40% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Genprex	N/A	-247.32%	-176.73%

Genprex has lower revenue, but higher earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	104.58	-$28.74M	-$13.28	N/A
Genprex	N/A	N/A	-$16.23M	-$14.14	N/A

Summary

Synaptogenix beats Genprex on 7 of the 11 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNPX vs. The Competition

Export

Metric	Genprex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.26M	$3.40B	$6.41B	$12.58B
Dividend Yield	N/A	2.28%	2.75%	5.26%
P/E Ratio	-0.06	18.88	21.25	26.28
Price / Sales	N/A	334.55	561.56	114.71
Price / Cash	N/A	125.26	43.49	56.90
Price / Book	0.49	7.27	10.60	7.33
Net Income	-$16.23M	$24.20M	$3.56B	$337.06M
7 Day Performance	-5.07%	4.19%	2.97%	3.43%
1 Month Performance	-10.40%	9.51%	6.25%	7.24%
1 Year Performance	-95.32%	63.47%	36.72%	37.97%

Genprex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNPX Genprex	0.9569 of 5 stars	$0.78 -1.9%	N/A	-94.3%	$8.26M	N/A	N/A	20
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
ALGS Aligos Therapeutics	3.3897 of 5 stars	$5.78 +1.1%	$37.20 +544.2%	+0.0%	$35.75M	$2.19M	N/A	90	Analyst Forecast Gap Up
DARE Dare Bioscience	2.1877 of 5 stars	$2.38 -1.2%	$10.00 +320.2%	-20.6%	$35.65M	$1.03M	N/A	30	Short Interest Increase
VIRI Virios Therapeutics	N/A	$1.84 -0.5%	N/A	-70.0%	$35.44M	N/A	N/A	5	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNPX) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genprex (GNPX) Competitors

GNPX vs. ADXS, ALGS, DARE, VIRI, and TAOX

How does Genprex compare to Ayala Pharmaceuticals?

Summary

How does Genprex compare to Aligos Therapeutics?

Summary

How does Genprex compare to Dare Bioscience?

Summary

How does Genprex compare to Virios Therapeutics?

Summary

How does Genprex compare to Synaptogenix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genprex (GNPX) Competitors

GNPX vs. ADXS, ALGS, DARE, VIRI, and TAOX

How does Genprex compare to Ayala Pharmaceuticals?

Do analysts prefer GNPX or ADXS?

Which has more volatility and risk, GNPX or ADXS?

Is GNPX or ADXS more profitable?

Which has higher valuation and earnings, GNPX or ADXS?

Do insiders & institutionals have more ownership in GNPX or ADXS?

Does the media favor GNPX or ADXS?

Summary

How does Genprex compare to Aligos Therapeutics?

Which has preferable valuation & earnings, ALGS or GNPX?

Do analysts recommend ALGS or GNPX?

Is ALGS or GNPX more profitable?

Which has more volatility & risk, ALGS or GNPX?

Do insiders & institutionals have more ownership in ALGS or GNPX?

Does the media favor ALGS or GNPX?

Summary

How does Genprex compare to Dare Bioscience?

Is GNPX or DARE more profitable?

Does the media prefer GNPX or DARE?

Which has better earnings and valuation, GNPX or DARE?

Do analysts rate GNPX or DARE?

Do institutionals & insiders believe in GNPX or DARE?

Which has more risk and volatility, GNPX or DARE?

Summary

How does Genprex compare to Virios Therapeutics?

Which has more risk & volatility, VIRI or GNPX?

Do institutionals & insiders have more ownership in VIRI or GNPX?

Which has preferable earnings & valuation, VIRI or GNPX?

Does the media favor VIRI or GNPX?

Do analysts prefer VIRI or GNPX?

Is VIRI or GNPX more profitable?

Summary

How does Genprex compare to Synaptogenix?

Do insiders and institutionals hold more shares of TAOX or GNPX?

Which has more volatility & risk, TAOX or GNPX?

Do analysts rate TAOX or GNPX?

Does the media favor TAOX or GNPX?

Is TAOX or GNPX more profitable?

Which has stronger valuation & earnings, TAOX or GNPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools